Document Detail


Carvedilol ameliorates sympathetic nerve sprouting and electrical remodeling after myocardial infarction in rats.
MedLine Citation:
PMID:  20359859     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: We hypothesized that carvedilol, a nonselective β-blocker, can exert antiarrhythmogenic effects by inhibiting sympathetic nerve sprouting and electrical remodeling at peri-infarct zones after myocardial infarction (MI).
METHODS: MI was induced by ligation of the coronary artery. The rats in the carvedilol group received 5.0mg/kg carvedilol twice a day. Eight weeks after MI, monophasic action potential duration (MAPD), effective refractory period (ERP) and the inducibility of ventricular arrhythmia at the peri-infarct zones were evaluated and compared with MI rats. After these studies, the expression of growth associated protein 43 (GAP43) and tyrosinehydroxylase (TH) at the peri-infarct zones were examined by western blot and RT-PCR analysis.
RESULTS: Eight weeks after surgery, carvedilol shortened the duration of the MAPD determined as 20% (MAPD(20)) and 90% (MAPD(90)) repolarization time (33 ± 9 ms and 110 ± 18 ms vs 21 ± 6 ms and 76 ± 13 ms, both P<0.05) and ERP (76 ± 15 ms vs 62 ± 12 ms, P<0.05), respectively. Carvedilol decreased the inducibility of ventricular arrhythmia after MI (76% vs 32%, P<0.05). The expression of GAP43 and TH were suppressed by carvedilol after MI.
CONCLUSION: Carvedilol exerts antiarrhythmogenic effects by ameliorating sympathetic nerve sprouting and electrical remodeling in MI rats. The effects of carvedilol on amelioration of electrical remodeling may be partly related to the inhibition of sympathetic remodeling.
Authors:
Huazhi Wen; Hong Jiang; Zhibing Lu; Xiaorong Hu; Bo He; Qizhu Tang; Congxin Huang
Related Documents :
16814669 - Post-reperfusion myocardial infarction: long-term survival improvement using adenosine ...
2677209 - Comparability of echocardiography and chest x-ray following myocardial infarction.
3394629 - Electrocardiographic diagnosis of myocardial infarction in the presence of complete lef...
16460969 - A percutaneous swine model of myocardial infarction.
19559709 - Extracellular matrix turnover and signaling during cardiac remodeling following mi: cau...
15819299 - Antecedent hypertension interacts with adverse ventricular remodeling after myocardial ...
12939209 - Risk stratification after acute myocardial infarction by heart rate turbulence.
3812189 - Cardiac size and motion during water immersion: implications for volume homeostasis.
15063249 - Role of transvalvular gradient in outcome from valve replacement for aortic stenosis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-02-25
Journal Detail:
Title:  Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie     Volume:  64     ISSN:  1950-6007     ISO Abbreviation:  Biomed. Pharmacother.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-13     Completed Date:  2011-02-14     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8213295     Medline TA:  Biomed Pharmacother     Country:  France    
Other Details:
Languages:  eng     Pagination:  446-50     Citation Subset:  IM    
Copyright Information:
2010 Elsevier Masson SAS. All rights reserved.
Affiliation:
Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan University, 238, Jiefang Road, Wuchang, Wuhan 430060, PR China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Action Potentials
Adrenergic beta-Antagonists / pharmacology*
Animals
Arrhythmias, Cardiac / metabolism,  physiopathology
Autonomic Pathways / metabolism,  physiopathology
Carbazoles / pharmacology*
GAP-43 Protein / metabolism
Heart / innervation,  physiopathology
Male
Myocardial Infarction / drug therapy*,  metabolism,  physiopathology
Propanolamines / pharmacology*
RNA, Messenger / metabolism
Random Allocation
Rats
Rats, Wistar
Sympathetic Nervous System / drug effects*,  physiopathology
Tyrosine 3-Monooxygenase / metabolism
Ventricular Remodeling / drug effects
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Carbazoles; 0/GAP-43 Protein; 0/Propanolamines; 0/RNA, Messenger; 0K47UL67F2/carvedilol; EC 1.14.16.2/Tyrosine 3-Monooxygenase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing p...
Next Document:  Comparison of voice-use profiles between elementary classroom and music teachers.